In the immune system, MHCI is well known for its ability to suppress NK cell and T cell function, providing a key mechanism for preventing autoreactivity. MHCI expression in the CNS is generally low. However, MHCI expression is locally induced on neurons following kainate-induced seizures and CNS injury, and numerous studies have observed increases in MHCI expression in the CNS of patients with brain injury, stroke, epilepsy and neurodegenerative diseases. Recently, neuronal MHCI was shown to be involved in the elimination of inappropriate synaptic connections in the CNS. Moreover, our preliminary results indicate that MHCI can inhibit neuronal outgrowth in vitro. Based on these observations, we hypothesized that the induced expression of MHCI on neurons following injury might counteract neuronal repair responses in vivo. To test this hypothesis, we utilized a well-characterized model of compensatory neuronal sprouting that occurs following unilateral lesioning of the perforant path, combined with transgenic mice which were genetically engineered to express low levels of MHCI on CNS neurons. Our preliminary results indicate that although these transgenic mice had no apparent developmental CNS abnormalities, they have severely reduced compensatory sprouting responses following CNS injury. This proposal will further test the hypothesis that neuronal MHCI can inhibit compensatory neuronal sprouting responses. This will provide a foundation from which the role of MHCI in neurodevelopment and neuronal repair can be further assessed. This proposal opens a new area of research, the results of which may provide important conceptual advances. Conceivably, treatments that limit the neuroinhibitory effects of MHCI could lead to new clinical approaches to mitigate neuropathological disorders.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21NS047383-02
Application #
6897885
Study Section
National Institute of Neurological Disorders and Stroke Initial Review Group (NSD)
Program Officer
Hicks, Ramona R
Project Start
2004-07-01
Project End
2007-04-30
Budget Start
2005-05-01
Budget End
2007-04-30
Support Year
2
Fiscal Year
2005
Total Cost
$177,581
Indirect Cost
Name
University of California Los Angeles
Department
Pharmacology
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Bilousova, Tina; Dang, Hoa; Xu, Willem et al. (2012) Major histocompatibility complex class I molecules modulate embryonic neuritogenesis and neuronal polarization. J Neuroimmunol 247:1-8
Tian, Jide; Yong, Jing; Dang, Hoa et al. (2011) Oral GABA treatment downregulates inflammatory responses in a mouse model of rheumatoid arthritis. Autoimmunity 44:465-70
Wu, Zhongqi-Phyllis; Bilousova, Tina; Escande-Beillard, Nathalie et al. (2011) Major histocompatibility complex class I-mediated inhibition of neurite outgrowth from peripheral nerves. Immunol Lett 135:118-23
Wu, Zhongqi-Phyllis; Washburn, Lorraine; Bilousova, Tina V et al. (2011) Enhanced neuronal expression of major histocompatibility complex class I leads to aberrations in neurodevelopment and neurorepair. J Neuroimmunol 232:8-16
Washburn, Lorraine R; Zekzer, Dan; Eitan, Shoshana et al. (2011) A potential role for shed soluble major histocompatibility class I molecules as modulators of neurite outgrowth. PLoS One 6:e18439
Joseph, M Selvan; Bilousova, Tina; Zdunowski, Sharon et al. (2011) Transgenic Mice With Enhanced Neuronal Major Histocompatibility Complex Class I Expression Recover Locomotor Function Better After Spinal Cord Injury. J Neurosci 89:365-372
Escande-Beillard, Nathalie; Washburn, Lorraine; Zekzer, Dan et al. (2010) Neurons preferentially respond to self-MHC class I allele products regardless of peptide presented. J Immunol 184:816-23